Khrom Capital Management LLC Sells 410,393 Shares of Sotera Health (NASDAQ:SHC)

Khrom Capital Management LLC cut its stake in shares of Sotera Health (NASDAQ:SHC) by 33.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 807,416 shares of the company’s stock after selling 410,393 shares during the period. Sotera Health accounts for about 1.8% of Khrom Capital Management LLC’s investment portfolio, making the stock its 12th biggest holding. Khrom Capital Management LLC owned 0.29% of Sotera Health worth $9,584,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. CWM LLC increased its stake in Sotera Health by 86.1% during the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after acquiring an additional 993 shares during the period. Quest Partners LLC bought a new position in Sotera Health during the 4th quarter worth $139,000. Acadian Asset Management LLC increased its stake in Sotera Health by 728.0% during the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after acquiring an additional 8,248 shares during the period. Sandia Investment Management LP bought a new position in Sotera Health during the 1st quarter worth $120,000. Finally, Securian Asset Management Inc. increased its stake in shares of Sotera Health by 23.0% in the 1st quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock valued at $122,000 after purchasing an additional 1,900 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SHC. Barclays lifted their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and a consensus price target of $15.70.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 55.12% of the company’s stock.

Sotera Health Stock Performance

SHC stock opened at $16.64 on Tuesday. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46. The stock has a 50-day moving average price of $14.96 and a 200-day moving average price of $12.86. The firm has a market cap of $4.71 billion, a PE ratio of 87.58 and a beta of 2.07. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. The firm had revenue of $277.00 million during the quarter, compared to analyst estimates of $266.45 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 EPS. As a group, equities research analysts expect that Sotera Health will post 0.64 earnings per share for the current year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.